AU2001248301A1 - Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives for topical application to the skin - Google Patents

Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives for topical application to the skin

Info

Publication number
AU2001248301A1
AU2001248301A1 AU2001248301A AU4830101A AU2001248301A1 AU 2001248301 A1 AU2001248301 A1 AU 2001248301A1 AU 2001248301 A AU2001248301 A AU 2001248301A AU 4830101 A AU4830101 A AU 4830101A AU 2001248301 A1 AU2001248301 A1 AU 2001248301A1
Authority
AU
Australia
Prior art keywords
lipid
skin
drug delivery
delivery systems
topical application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001248301A
Inventor
Jesper Davidsen
Sven Frokjaer
Kent Jorgensen
Ole G. Mouritsen
Charlotte Vermehren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liplasome Pharma ApS
Original Assignee
Liplasome Pharma ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liplasome Pharma ApS filed Critical Liplasome Pharma ApS
Publication of AU2001248301A1 publication Critical patent/AU2001248301A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Cosmetics (AREA)

Abstract

The invention relates to targeting of diagnostic agents by use of lipid-based compositions. The invention is useful in the diagnosis of various disorders which are associated with or resulting from increased levels of extracellular PLA<SUB>2 </SUB>activity in the diseased tissue, e.g. cancer, infectious, and inflammatory conditions.
AU2001248301A 2000-04-12 2001-04-11 Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives for topical application to the skin Abandoned AU2001248301A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200000616 2000-04-12
DKPA200000616 2000-04-12
PCT/DK2001/000267 WO2001076555A2 (en) 2000-04-12 2001-04-11 Lipid-based drug delivery systems for topical application

Publications (1)

Publication Number Publication Date
AU2001248301A1 true AU2001248301A1 (en) 2001-10-23

Family

ID=8159422

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2001248303A Abandoned AU2001248303A1 (en) 2000-04-12 2001-04-11 Lipid-based systems for targeting diagnostic agents
AU2001248302A Abandoned AU2001248302A1 (en) 2000-04-12 2001-04-11 Lipid-based drug delivery systems against parasitic infections
AU2001248301A Abandoned AU2001248301A1 (en) 2000-04-12 2001-04-11 Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives for topical application to the skin

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AU2001248303A Abandoned AU2001248303A1 (en) 2000-04-12 2001-04-11 Lipid-based systems for targeting diagnostic agents
AU2001248302A Abandoned AU2001248302A1 (en) 2000-04-12 2001-04-11 Lipid-based drug delivery systems against parasitic infections

Country Status (11)

Country Link
US (4) US20030170297A1 (en)
EP (3) EP1272225B1 (en)
JP (3) JP2003530338A (en)
AT (2) ATE336267T1 (en)
AU (3) AU2001248303A1 (en)
CY (2) CY1105792T1 (en)
DE (3) DE60122304T2 (en)
DK (3) DK1272225T3 (en)
ES (3) ES2280355T3 (en)
PT (3) PT1272161E (en)
WO (3) WO2001076556A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020001614A1 (en) * 2000-02-10 2002-01-03 Kent Jorgensen Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof
WO2002085391A1 (en) * 2001-04-24 2002-10-31 Luis Alberto Costa Use of a phospholipase a2 for the preparation of pharmaceutical and/or cosmetic compositions for the local and/or systematic treatment and/or prevention of diseases and/or processes caused by intra- and extracellular pathogens expressing membrane phospholipids
US20050123925A1 (en) * 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20050112065A1 (en) * 2003-07-09 2005-05-26 Drummond Daryl C. Remote detection of substance delivery to cells
US20050266066A1 (en) * 2003-10-20 2005-12-01 Nof Corporation Phospholipid membrane preparation
WO2005077963A1 (en) * 2004-01-16 2005-08-25 Institut Superieur Agricole De Beauvais Saccharide and itol derivatives having an o-alkyl group or an o-alkyl group and an o-n butanyl group, uses as medicines in tumoral or benign proliferative pathologies
US20080113014A1 (en) * 2004-01-28 2008-05-15 Ltt Bio-Pharma Co., Ltd. Method for Screening for Compounds Safe for Gastric Mucosa
DE102004010387A1 (en) * 2004-03-03 2005-09-22 Siemens Ag Contrast agent for X-ray computed tomography
WO2006086992A2 (en) * 2005-02-18 2006-08-24 Liplasome Pharma A/S Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
JP2006248978A (en) 2005-03-10 2006-09-21 Mebiopharm Co Ltd New liposome preparation
US20090110633A1 (en) * 2005-03-14 2009-04-30 Shiladitya Sengupta Nanocells for Diagnosis and Treatment of Diseases and Disorders
PL1933809T3 (en) * 2005-10-11 2012-09-28 Yissum Research Development Company Of The Hebrew Univ Of Jerusalem Compositions for nasal delivery
WO2007071402A1 (en) * 2005-12-23 2007-06-28 Jado Technologies Gmbh Means and methods for the treatment and prevention of allergic diseases
JP2011026294A (en) * 2009-06-26 2011-02-10 Canon Inc Compound
US8993715B2 (en) * 2009-07-06 2015-03-31 Canon Kabushiki Kaisha Labeled protein and method for obtaining the same
DE112010003355T5 (en) 2009-08-21 2012-07-12 Targeted Delivery Technologies Ltd. Vesicular formulations
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
DK177529B1 (en) * 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
WO2011102905A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion diagnostic delivery system
WO2011102906A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion delivery system
WO2011102904A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion therapeutic delivery system
JP2015509507A (en) * 2012-03-09 2015-03-30 ウニベルシダーヂ フェデラル ヂ ミナス ジェライス−ウエフィエミジェー Pharmaceutical composition containing conventional and long-circulating liposomes for treating visceral leishmaniasis
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
WO2014047116A1 (en) * 2012-09-18 2014-03-27 Comfort Care For Animals Llc Encapsulating liposomes
LT3316856T (en) 2015-06-30 2021-07-12 Sequessome Technology Holdings Limited Blended formulations
WO2018087720A1 (en) 2016-11-14 2018-05-17 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0714865B2 (en) * 1986-10-28 1995-02-22 武田薬品工業株式会社 Liposome preparation and method for producing the same
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5925375A (en) * 1987-05-22 1999-07-20 The Liposome Company, Inc. Therapeutic use of multilamellar liposomal prostaglandin formulations
FR2638639A1 (en) * 1988-11-08 1990-05-11 Parincos Parfumerie Cosmet Int Composition and method for the production of oligolamellar liposomes for the purpose of application in cosmetology and topical dermatology
US5153000A (en) * 1988-11-22 1992-10-06 Kao Corporation Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
US4874794A (en) * 1989-04-28 1989-10-17 Lidak Biopharmaceuticals Inflammatory disease treatment
JPH0370491A (en) 1989-08-04 1991-03-26 Toshiba Corp Motor controller
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
CA2067754C (en) * 1990-08-24 2002-06-04 Gregor Cevc Preparation for the application of agents in mini-droplets
US5723115A (en) * 1991-05-02 1998-03-03 W. Alton Jones Cell Science Center, Inc. Inhibition of adipose tissue development and obesity
US5484911A (en) * 1993-04-01 1996-01-16 Health Research, Inc. Nucleoside 5'-diphosphate conjugates of ether lipids
DE4408011C1 (en) * 1994-03-10 1995-11-02 Max Delbrueck Centrum Liposomes for tumour therapy
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US5942246A (en) * 1996-02-16 1999-08-24 The Liposome Company, Inc. Etherlipid containing multiple lipid liposomes
US5827836A (en) 1996-11-15 1998-10-27 Clarion Pharmaceuticals Inc. Retinoid glycerol phospholipid conjugates
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6444640B1 (en) * 1999-09-30 2002-09-03 Ludwig Institute For Cancer Research Compositions of trail and DNA damaging drugs and uses thereof

Also Published As

Publication number Publication date
US20030162748A1 (en) 2003-08-28
WO2001076555A2 (en) 2001-10-18
US7368254B2 (en) 2008-05-06
WO2001076644A2 (en) 2001-10-18
ES2270991T3 (en) 2007-04-16
PT1272160E (en) 2007-04-30
US20070134153A1 (en) 2007-06-14
WO2001076556A3 (en) 2002-07-11
EP1272225B1 (en) 2006-08-16
DE60126072D1 (en) 2007-03-08
AU2001248302A1 (en) 2001-10-23
ATE336267T1 (en) 2006-09-15
EP1272160B1 (en) 2007-01-17
JP2003530339A (en) 2003-10-14
EP1272161A2 (en) 2003-01-08
DK1272160T3 (en) 2007-05-21
WO2001076555A3 (en) 2002-03-14
JP2003530338A (en) 2003-10-14
EP1272161B1 (en) 2008-01-02
PT1272161E (en) 2008-02-08
DK1272161T3 (en) 2008-05-19
DE60122304D1 (en) 2006-09-28
JP2003530362A (en) 2003-10-14
ES2280355T3 (en) 2007-09-16
WO2001076556A2 (en) 2001-10-18
US20030170297A1 (en) 2003-09-11
US7166297B2 (en) 2007-01-23
US20030175205A1 (en) 2003-09-18
PT1272225E (en) 2007-01-31
CY1105792T1 (en) 2011-02-02
CY1106462T1 (en) 2012-01-25
ATE382333T1 (en) 2008-01-15
DE60122304T2 (en) 2007-08-09
DE60132184D1 (en) 2008-02-14
AU2001248303A1 (en) 2001-10-23
DK1272225T3 (en) 2006-12-27
DE60132184T2 (en) 2009-01-15
ES2295149T3 (en) 2008-04-16
EP1272160A2 (en) 2003-01-08
DE60126072T2 (en) 2007-11-08
WO2001076644A3 (en) 2002-03-14
EP1272225A2 (en) 2003-01-08

Similar Documents

Publication Publication Date Title
AU2001248301A1 (en) Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives for topical application to the skin
AU6185398A (en) Charged lipids and uses for the same
CA2396186A1 (en) Agents for the treatment of skin disorders
TW200716661A (en) A novel triterpenic acid derivative and the skin external preparation containing the same
NO20075660L (en) Composition for the treatment of inflammatory diseases
GB0222495D0 (en) Compounds
AR024516A1 (en) BI-AROMATIC COMPOUNDS ANALOGS OF VITAMIN D, ITS USE, PHARMACEUTICAL COMPOSITION AND COSMETIC COMPOSITION THAT INCLUDE AT LEAST ONE OF SUCH COMPOUNDS AND USE OF SUCH COSMETIC COMPOSITION.
MXPA05011208A (en) Topical formulation of ivermectin for the treatment of dermatological conditions.
CU23208A3 (en) OXAZOLIDINONAS REPLACED AND ITS USE IN THE FIELD OF THE SANGUINEA COAGULATION
WO2001093841A3 (en) Barbituric acid analogs as therapeutic agents
BR9810312A (en) Pharmaceutical composition that has marked antitumor activity and / or reduced side effects containing an antitumor agent and a derivative of hydroxy acid
PT902789E (en) ANDROSTENE DERIVATIVES
DE60211935D1 (en) ALKANDIOL DERIVATIVES FOR THE TREATMENT OF BONE DISEASES
CA2392165A1 (en) Vitamin d analogues
PT1272199E (en) COMBINATION THERAPIES WITH LESAO VASCULAR ACTIVITY
CA2264979A1 (en) Dicyclic-aromatic compounds and their application in human and veterinary medicine, as well as in cosmetics
BG106155A (en) Novel derivatives and analogues of galanthamin
CA2392168A1 (en) Vitamin d analogues
EP1736470A3 (en) Pyrimidine derivatives as CB2 cannabinoid receptor modulators
BR0009211A (en) Resorcinol derivatives
ATE233246T1 (en) HYDANTOIN DERIVATIVES AS INTERMEDIATE PRODUCTS FOR PHARMACEUTICAL ACTIVE INGREDIENTS
RS11104A (en) Combined preparations,containing 1,4- benzothiepine-1,1- dioxide derivatives and other active substances, and the use thereof
CA2334843A1 (en) Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics
BR0009194A (en) Composition of resorcinol
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses